
|Articles|December 4, 2009
FDA approves therapy for advanced renal cell carcinoma
Author(s)Urology Times staff
The FDA has approved GlaxoSmithKline's pazopanib (Votrient) to treat patients with advanced renal cell carcinoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












